Eftilagimod alpha

Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Dec. 08, 2025 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, and along with its subsidiaries, hereafter referred to as “Dr. Reddy’s”), today announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, have entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China. Efti is Immutep’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma. The terms of the licensing agreement provide Immutep with significant milestones and preserves its ability to capture material future upside in the licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr. Reddy’s in the licensed markets, while Immutep retains all rights to the product in the key pharmaceutical markets, including North America, Europe, and Japan. Additionally, as per the agreement, Immutep will receive from Dr. Reddy’s an upfront payment of USD 20 million (~AUD 30.2 million). It is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales in these markets. “This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer treatment. Efti is a novel immunotherapy with the potential to set a new standard of care in combination with pembrolizumab (Keytruda®) and chemotherapy as first-line therapy for non-small cell lung cancer. Its broad potential extends to other major cancers across multiple stages of disease. Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed markets,” stated M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s. “This agreement with Dr. Reddy’s marks a significant milestone for Immutep and further validates the potential of efti. Dr. Reddy’s proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our innovation and serve a large number of patients across the globe. Additionally, this partnership allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets such as North America, Europe, and Japan, and ensures we remain very well-positioned for future value creation,” said Marc Voigt, CEO of Immutep. Efti is a first-in-class soluble LAG-3 protein and MHC Class II agonist delivered subcutaneously that uniquely activates antigen-presenting cells or APCs (e.g., dendritic cells, monocytes) via major histocompatibility complex (MHC) class II ligands. As an MHC Class II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important co-stimulatory signals & cytokines that further boost the immune system’s ability to combat cancer. Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC) in a pivotal Phase III trial called TACTI-004 (KEYNOTE-F91), as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy. This has been demonstrated across early-stage trials in NSCLC and HNSCC, which have laid the foundation for the larger randomized clinical trial in NSCLC. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, Dr. Reddy’s offers a portfolio of products and services including APIs, generics, branded generics, biosimilars, innovative drugs, and OTC. Our major therapeutic areas of focus are oncology, gastroenterology, cardiology, diabetology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, Dr. Reddy’s continues to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. The content above comes from the network. if any infringement, please contact us to modify.

A new deal with Immutep notably doesn’t give Dr. Reddy’s Laboratories the rights to eftilagimod in the key markets of North America, Europe, China and Japan.\n Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key markets.Immutep demonstrated back in May that a combination of the therapy, called eftilagimod alpha, and Merck & Co.’s blockbuster cancer drug Keytruda helped patients live a median of 17.6 months when used as first-line therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).Sydney-based Immutep is currently evaluating the therapy in a phase 3 trial for advanced or metastatic non-small cell lung cancer as well as continuing to explore its potential in head and neck cancer, breast cancer and soft tissue sarcoma.This morning’s deal sees Dr. Reddy’s pay $20 million upfront for the exclusive rights to eftilagimod, with Immutep also eligible for up to $349.5 million in regulatory and commercial milestone payments along with double-digit royalties on commercial sales in the relevant markets.However, the deal notably doesn’t give the Indian generics giant the rights to eftilagimod in the key markets of North America, Europe, China and Japan.Immutep also retains the rights to manufacture the drug across the globe, meaning it will supply eftilagimod to Dr. Reddy’s in the markets the Indian company has taken ownership of.While Dr. Reddy’s won’t be able to take advantage of eftilagimod in the most lucrative global markets, the Hyderabad, India-based company remains pleased with the deal, placing the agreement in the context of its “continuous efforts to deliver first-in-class and innovative therapies for cancer treatment” and continue to broaden its offerings outside of its base generics business. “Efti is a novel immunotherapy with the potential to set a new standard of care in combination with Keytruda and chemotherapy as first-line therapy for non-small cell lung cancer,” M.V. Ramana, CEO, branded markets (India and emerging markets) at Dr. Reddy’s, said in a statement. “Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed markets,” Ramana added.Immutep CEO Marc Voigt said the partnership “allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets such as North America, Europe, and Japan, and ensures we remain very well-positioned for future value creation.”Voigt has previously touted a combo of eftilagimod and Keytruda as offering a potential immunotherapy-only regimen, compared to the standards today for PD-L1-negative patients that all include chemotherapy. Eftilagimod is a LAG-3 fusion protein, which activates antigen-presenting cells to boost an immune response.Immutep is hoping to carve out a niche market from PD-L1-negative disease, which makes up about 20% of first-line HNSCC patients. As Voigt noted back in May, there’s a lack of competitor chemo-free trials targeting this population.